|
|
Post by dg1111 on Mar 1, 2016 16:34:41 GMT -5
after seeing this, i'm nearly 100% certain that this pertains to weed, and if so, their royalty percentage will pay off big in the years to come as more and more states legalize for medicinal purposes. way to uh, blaze, the trail MNKD! What would an approval process look like in this case? Is the fda involved at all? And would they be looking at medicinal use only or also recreational? Recreational use is also being legalized in more and more states. |
|
|
|
Post by kc on Mar 1, 2016 16:38:31 GMT -5
after seeing this, i'm nearly 100% certain that this pertains to weed, and if so, their royalty percentage will pay off big in the years to come as more and more states legalize for medicinal purposes. way to uh, blaze, the trail MNKD! Yep it looks like weed... Smells like weed too.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Mar 1, 2016 16:42:47 GMT -5
|
|
|
|
Post by sccrbrg on Mar 1, 2016 16:49:55 GMT -5
Am I the only one that doesn't see this as a good thing?
Nearly every marijuana stock I have ever tracked has eventually imploded.
Not to mention any negative sentiment that could become attached to Afrezza or any of the other TS medications. Seems like a bad move.
|
|
|
|
Post by bioexec25 on Mar 1, 2016 16:57:13 GMT -5
Am I the only one that doesn't see this as a good thing? Nearly every marijuana stock I have ever tracked has eventually imploded. Not to mention any negative sentiment that could become attached to Afrezza or any of the other TS medications. Seems like a bad move. I don't see it as good or bad at this point. The plant based, non-bloated bureaucratic FDA is interesting to me as a share holder. Especially if this science can make the best of the therapeutic more consistent and predictable. |
|
|
|
Post by kc on Mar 1, 2016 17:31:41 GMT -5
Am I the only one that doesn't see this as a good thing? Nearly every marijuana stock I have ever tracked has eventually imploded. Not to mention any negative sentiment that could become attached to Afrezza or any of the other TS medications. Seems like a bad move. I don't see it as good or bad at this point. The plant based, non-bloated bureaucratic FDA is interesting to me as a share holder. Especially if this science can make the best of the therapeutic more consistent and predictable. There is one that has done well and it is based in the UK. They Trade on NASDAQ. GWPH... finance.yahoo.com/q?s=GWPH So the potential for Mannkind in this field is huge.
GWPH They are in the Medical Marijuana business and have been successful and also sells with Bayer as a partner.
The marijuana used to make Sativex is grown by the medicine’s developer and producer, GW Pharmaceuticals in the UK while Bayer Pharmaceuticals distributes Sativex in Europe and North America. It is available or approved in 24 countries worldwide including the UK, New Zealand, Canada, Italy, France, Israel, Iceland, Spain, and throughout Scandinavia 
The have also been working on Diabetes /Metabolic syndrome treatment - obesity
Diabetes/Metabolic Disease
GW embarked on a programme of three Phase IIa clinical trials to evaluate a range of GW cannabinoids as treatments for features of Type 2 diabetes and metabolic syndrome. GWP42004, which features Tetrahydrocannabivarin (THCV) as the primary cannabinoid, produced desirable effects in fasting plasma glucose, fasting insulin, beta cell function, adiponectin, systolic blood pressure and inflammatory cytokines. The studies were designed with lipids as the primary endpoint and as such the patients recruited had normal HbA1c levels (deviations of which are the usual gold standard for diabetes trials). Therefore GW are now planning a larger placebo controlled Phase 2 dose ranging trial of GWP42004 in patients with uncontrolled HbA1c levels, which is expected to start in the first half of 2014, to evaluate its efficacy as an oral anti-diabetic medicine.
GW’s clinical study programme seeks to build upon pre‑clinical data demonstrating the desirable effects of GW cannabinoids on plasma insulin, leptin and adiponectin levels. In addition, these results have shown a reduction in total cholesterol with an increase in the proportion of HDL (good) cholesterol. GW cannabinoids have also shown the ability to reduce liver fat levels in animal models of hepatic steatosis. Recent findings include the observation in a rodent model of diabetes that cannabinoids are able to protect the insulin‑producing cells of pancreatic islets cells.
www.gwpharm.com/Diabetes.aspx www.ncbi.nlm.nih.gov/pubmed/23712280%20 www.ncbi.nlm.nih.gov/pubmed/21484568
|
|
|
|
Post by kball on Mar 1, 2016 18:00:38 GMT -5
Wow, I thought they were all high BEFORE
|
|
|
|
Post by bthomas55ep on Mar 1, 2016 18:00:47 GMT -5
Am I the only one that doesn't see this as a good thing? Nearly every marijuana stock I have ever tracked has eventually imploded. Not to mention any negative sentiment that could become attached to Afrezza or any of the other TS medications. Seems like a bad move. I also don't see it as necessarily a negative. Mannkind will not be a marijuana stock. Regardless of how RLS does in the long run, the $100+ Million in Milestone payments as RLS works through the proof of concept and then the potential of getting royalty payments from RLS to the degree they are successful only gives Mannkind the much needed cash to develop their own portfolio. This product will not be Mannkind's product and it is feasible that RLS branding may even make it hard to determine who the delivery technology belongs to unless you dig through the filings. Hopefully there will be many many T/S products owned by other companies in addition to a handful of Mannkind owed drugs (including Afrezza) which can all come together to make a multi-billion revenue company. The fact that one of those drugs pumping cash in comes as a royalty from a medical marijuana company should make no negative difference. Right now, it represents one of the only known potential life-saving cash sources. IMO. |
|
|
|
Post by kbrion77 on Mar 1, 2016 18:44:35 GMT -5
Am I the only one that doesn't see this as a good thing? Nearly every marijuana stock I have ever tracked has eventually imploded. Not to mention any negative sentiment that could become attached to Afrezza or any of the other TS medications. Seems like a bad move. I think it's a great thing. It is another avenue of revenue for their business model. 1. Proprietary Product (Afrezza), 2. Technosphere Formulations to license and 3. Technosphere Technology to license. I hope to see the day where all 3 avenues are strong and generating significant amounts of revenue. |
|
|
|
Post by patten1962 on Mar 1, 2016 18:58:08 GMT -5
Am I the only one that doesn't see this as a good thing? Nearly every marijuana stock I have ever tracked has eventually imploded. Not to mention any negative sentiment that could become attached to Afrezza or any of the other TS medications. Seems like a bad move. I think it's a great thing. It is another avenue of revenue for their business model. 1. Proprietary Product (Afrezza), 2. Technosphere Formulations to license and 3. Technosphere Technology to license. I hope to see the day where all 3 avenues are strong and generating significant amounts of revenue. Wad just watching Mad Money. DEXCOM CEO was just on. They are partnered with Google "Life sciences" . To me it's the perfect fit. Can't wait until April 5th.. |
|
|
|
Post by tayl5 on Mar 1, 2016 21:42:35 GMT -5
after seeing this, i'm nearly 100% certain that this pertains to weed, and if so, their royalty percentage will pay off big in the years to come as more and more states legalize for medicinal purposes. way to uh, blaze, the trail MNKD! Given the very large range of plant-derived therapeutics that could be involved, what leads you to infer that this has anything to do with weed? There are many compounds that are too difficult to synthesize or can be extracted less expensively that could be delivered with TS. |
|
|
|
Post by seanismorris on Mar 1, 2016 23:20:36 GMT -5
It's a Chinese conspiracy!
Pot TS goes OTC, US productivity drops 25% and China takes over as the sole SuperPower ; )
Sorry must be a slow news day. If you are one of those riveted watching MNKD bounce around 1$ this product is for you.
|
|
|
|
Post by kball on Mar 2, 2016 6:55:03 GMT -5
It's a Chinese conspiracy! Pot TS goes OTC, US productivity drops 25% and China takes over as the sole SuperPower ; ) Sorry must be a slow news day. If you are one of those riveted watching MNKD bounce around 1$ this product is for you.Ha. Not to mention if you've held all the way down. Something a lot stronger required for selling after the beat down. Better living through chemistry |
|
|
|
Post by mnholdem on Mar 2, 2016 7:31:27 GMT -5
You guys might have it all wrong with the idea that it's China backing up inhaled cannabis.
Think Frito-Lay... and somebody please pass me the Doritos.    |
|
|
|
Post by kc on Mar 2, 2016 16:10:59 GMT -5
If it's good for Frito-Lay that it's great for me. I have owned PEP for over 30 years. So let's have some munchies
|
|
